Scott L Friedman, MD
img_Scott L Friedman
DEAN FOR THERAPEUTIC DISCOVERY
PROFESSOR | Medicine, Liver Diseases
PROFESSOR | Pharmacological Sciences
Are you a patient?
Specialties
Internal Medicine, Gastroenterology
Research Topics
Aerodigestive Tract, Anti-Tumor Therapy, Apoptosis/Cell Death, Autophagy, Biomedical Sciences, Cancer Genetics, Cell Biology, Cell Transformation, Developmental Biology, Drug Resistance, Endothelial Cells, Epithelial Cells, Extracellular Matrix, Fibrosis, Gene Regulation, Growth Factors and Receptors, Hepatitis C Virus, Integrins, Knockout Mice, Liver, Macrophage, Metastasis, Molecular Biology, Organogenesis, Oxidative Stress, Phosphorylation, Proteases, Receptors, Signal Transduction, Transcription Factors, Transcriptional Activation and Repression, Transgenic Mice, Tumor Suppressor Genes, Tumorigenesis, Vascular Development, Wound Healing
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Mechanisms of Hepatic Fibrosis and Cancer
Dr. Friedman is the Director of both the Division of Liver Diseaases and the Fibrosis Research Center, and is co-Director of the Tisch Cancer Institute Liver Cancer Program

Specific Clinical/Research Interest:
  • Cellular and molecular mechanisms of hepatic fibrosis and cancer
  • Diagnosis and development of anti-fibrotic therapies for patients with chronic liver disease
  • Clinical trials of antifibrotic therapies in patients with chronic liver disease




Current Students: Billie Bian PhD Student, Fatemah Parvin-Nejad, MD Student; Benjamin Wooden, MD Student

Current Postdoctoral Fellows: Youngjoon Yoon, MD; Takuma Tsuchida PhD;

Research Personnel: Hsin Chou, M.S. (Lab Manager); Dipankar Bhattacharya, M.S.

Summary of Research Studies:

Our work explores the molecular mechanisms of wound healing and fibrosis in liver and how they contribute to liver cancer. We use a variety of animal and cell culture models to identify key inflammatory mediatiors and signaling molecules regulating the activation of hepatic stellate cells, the principle fibrogenic cells in liver. Additionally, we test candidate antifibrotic lead compounds to develop potential new therapies for patients with chronic fibrosing liver diseases. Specific projects include:

- Molecular mechanisms of hepatic stellate cell activation and the cell's role iin hepatic regeneration, immunity and repair
-Testing of antifibrotic lead compounds in animal models
-Clinical trials of antifibrotic therapies in patients with chronic liver disease


BS, Rensselaer Polytechnic Institute

MD, Icahn School of Medicine at Mount Sinai

Residency, Internal Medicine, Beth Israel Deaconess Medical Center-Main Campus

Residency, Internal Medicine, Beth Israel Deaconess Medical Center-Main Campus

Fellowship, Gastroenterology, University of CA at San Francisco Medical Center

Certifications

American Board of Internal Medicine

2016

Am Assn for the Study of Liver Diseases Distinguished Achievement Award

AASLD

2016

American Liver Foundation Distinguished Achievement Award

American Liver Foundation

2015

Emmet B Keeffe Mentoring Award

Recognizes outstanding mentorship in the field of hepatology

2015

Fellow, American Assn for the Advancement fo Science

AAAS

2015

Maud Menten Honorary Lecture

U. Pittsburgh

2015

Burton Combes Memorial Lecture

UT Southwestern GI Division

2015

Charles Lieber Memorial Lecture

American Gastroenterological Assn

2014

China Friendship Award

Chinese Government, presented by the Premier of China

2014

The Jacobi Medallion

The Icahn School of Medicine at Mount Sinai

2014

Salute to Excellence Award

American Liver Foundation, San Francisco Chapter

2014

Fellow

Am Assn for the Study of Liver Diseases

2014

President

American Assn for the Study of Liver Diseases

2014

Rao Honorary Lecture

Feinberg School of Medicine, Northwestern U.

2013

International Recognition Award

European Assn for the Study of LIver

2013

Shanghai Magnolia Gold Award

City of Shanghai

2012

Master Educator Recognition

Mount Sinai Institute for Medical Education

2010

Englert Lecture

University of Utah Dept of Medicine

2009

Rafael Research Alumni Visiting Scientist

Rambam Hospital, Haifa, Israel

2009

Sheila Sherlock Lecture

British Assn for Gastroenterology, Liverpool, UK

2008

Sackler Distinguished Lectureship

Tel Aviv University, Israel

2008

Fellow of the American Gastroenterological Assn

2008

Ken & Louise Goldberg Visiting Professor

Brigham and Women's Hospital, Boston MA

2006

Solomon Berson Dept of Medicine Housestaff Teaching Award

2004

International Hans Popper Research Prize

Falk foundation

2003

International Hans Popper Award to Outstanding Researcher in Hepatology

1995

Fulbright Senior Scholar Award

1979

Arthur H. Aufses Sr., Prize in Surgery

Mount Sinai School of Medicine

The Dawn of Translation in NASH and Hepatic Fibrosis
Drug, Diagnostic and Device Development: From Scientific Findings to FDA Approval
Scott Friedman, MD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Friedman during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Boston Pharmaceuticals
  • Merck Pharmaceuticals
  • Takeda Pharmaceuticals Of North America, Inc.
  • Pfizer Pharmaceuticals
  • Novartis Pharmaceutical Corporation
  • Variant Bio
  • HepGene
  • Ochre Bio
  • Junevity
  • 89bio Inc
  • Sunbird BIo
  • Boehringer Ingelheim, Ltd.
  • Lerna Therapeutics
  • Laekna
  • Macomics
  • Kriya
  • In Sitro
  • Satellite Bio
  • Morphic Therapeutic
  • Gordian Biotechnology
  • Surrozen
  • Acceler, Korea
  • AgoMab
  • Overtone Therapeutics
  • Therasid Bio
  • Prosciento Research
  • Korro BIo
  • Resolution Therapeutics
  • North Sea Therapeutics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • In Sitro
  • Sagimet Biosciences
  • Scholar Rock
  • PharmaIN
  • Laekna
  • Gordian Biotechnology
  • Morphic Therapeutics
  • North Sea Therapeutics
  • Ochre Bio

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.